EXAGEN INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent
EXAGEN INC. (XGN) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent of -0.60% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther · last filed 2026-03-10
- EXAGEN INC. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2025 was -0.60%.
- EXAGEN INC. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2024 was -0.60%.
- EXAGEN INC. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2022 was -0.90%.
- EXAGEN INC. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2021 was -1.10%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 12 month |
|---|---|
| 2025-12-31 | -0.60% 10-K · filed 2026-03-10 |
| 2024-12-31 | -0.60% 10-K · filed 2026-03-10 |
| 2022-12-31 | -0.90% 10-K · filed 2023-03-20 |
| 2021-12-31 | -1.10% 10-K · filed 2023-03-20 |
| 2020-12-31 | -1.10% 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |